-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Definium Therapeutics, Raises Price Target to $70

Benzinga·03/02/2026 14:03:38
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $55 to $70.